The Score: Nvidia, Constellation, Eli Lilly, Gap and More Stocks That Defined the Week

Tyson Foods, the largest meat supplier in the U.S., is set to close one of its major beef-processing plants after incurring losses exceeding $425 million this year, despite near record-high beef prices. This decision reflects ongoing challenges within the meat processing industry.

Eli Lilly has appointed Carolyn Bertozzi to its board of directors, effective December. Bertozzi is a renowned chemist and Nobel laureate, bringing significant expertise to the pharmaceutical company as it continues to expand its market presence.

The U.S. government is considering allowing Nvidia to sell its H200 chips to China, according to sources. This potential decision comes amid ongoing scrutiny of semiconductor sales to China, particularly in light of national security concerns. The H200 chips are significant for AI applications, and their sale could have implications for U.S.-China relations in the tech sector.

Nvidia CEO Jensen Huang expressed concerns about the company's position amid discussions of an AI bubble, stating that the market did not recognize the company's strong quarterly performance. Huang's comments were revealed in a leaked meeting, highlighting the challenges Nvidia faces despite its recent successes.

The WSJ Dollar Index rose by 0.92% this week, reaching a value of 97.53. This increase comes after a previous decline of 0.1%, which ended a four-day winning streak for the index. The fluctuations in the index reflect ongoing volatility in the currency markets.

Investors are expressing concerns that the artificial intelligence (AI) sector may be experiencing a bubble, particularly affecting stocks associated with OpenAI, SoftBank, and Oracle. Despite strong earnings from Nvidia and the successful launch of Alphabet's Gemini 3 Pro AI model, stocks related to OpenAI are declining. This trend indicates a selective market reaction within the tech industry, raising questions about the sustainability of AI investments.

Eli Lilly has become the first pharmaceutical company to achieve a market value of $1 trillion, driven by a nearly 40% surge in its shares this year. This growth is largely attributed to the strong demand for its weight-loss and diabetes medications, particularly GLP-1 drugs.

Eli Lilly, a 150-year-old pharmaceutical company based in Indianapolis, has become the first healthcare company to reach a market value of $1 trillion. This milestone is largely attributed to its success in the GLP-1 weight loss drug market, particularly with products like Zepbound and Mounjaro.